BioMark Diagnostics Inc. (BUX.CN)
CAD 0.25
(0.0%)
CAD 0.25
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.31 Million CAD | 1.83% |
| 2022 | -1.84 Million CAD | -43.33% |
| 2021 | -1.28 Million CAD | -17.41% |
| 2020 | -1.09 Million CAD | 7.55% |
| 2019 | -1.18 Million CAD | -116.81% |
| 2018 | -545.61 Thousand CAD | 24.92% |
| 2017 | -726.74 Thousand CAD | -0.8% |
| 2016 | -721 Thousand CAD | 48.78% |
| 2015 | -1.4 Million CAD | 51.2% |
| 2014 | -2.88 Million CAD | -1493.6% |
| 2013 | -180.99 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -604.3 Thousand CAD | -21.53% |
| 2023 FY | -1.8 Million CAD | 1.83% |
| 2023 Q2 | -386.25 Thousand CAD | 6.47% |
| 2023 Q1 | -412.96 Thousand CAD | 12.47% |
| 2023 Q3 | -440.81 Thousand CAD | -14.12% |
| 2023 Q4 | -497.24 Thousand CAD | -12.8% |
| 2022 Q1 | -395.68 Thousand CAD | 47.02% |
| 2022 FY | -1.84 Million CAD | -43.33% |
| 2022 Q4 | -471.81 Thousand CAD | -27.03% |
| 2022 Q3 | -371.41 Thousand CAD | 25.4% |
| 2022 Q2 | -497.87 Thousand CAD | -25.83% |
| 2021 Q2 | -154.91 Thousand CAD | 45.76% |
| 2021 FY | -1.28 Million CAD | -17.41% |
| 2021 Q4 | -746.81 Thousand CAD | -234.31% |
| 2021 Q3 | -223.39 Thousand CAD | -44.2% |
| 2021 Q1 | -285.62 Thousand CAD | 49.64% |
| 2020 FY | -1.09 Million CAD | 7.55% |
| 2020 Q4 | -567.14 Thousand CAD | -192.06% |
| 2020 Q2 | -187.45 Thousand CAD | -40.1% |
| 2020 Q3 | -194.18 Thousand CAD | -3.59% |
| 2020 Q1 | -133.8 Thousand CAD | 52.16% |
| 2019 Q3 | -672.89 Thousand CAD | -395.04% |
| 2019 Q4 | -279.67 Thousand CAD | 58.44% |
| 2019 FY | -1.18 Million CAD | -116.81% |
| 2019 Q1 | -120.55 Thousand CAD | 2.16% |
| 2019 Q2 | -135.92 Thousand CAD | -12.75% |
| 2018 FY | -545.61 Thousand CAD | 24.92% |
| 2018 Q4 | -123.21 Thousand CAD | 26.95% |
| 2018 Q3 | -168.66 Thousand CAD | -5.05% |
| 2018 Q1 | -110.91 Thousand CAD | 21.83% |
| 2018 Q2 | -160.55 Thousand CAD | -44.76% |
| 2017 Q3 | -176.37 Thousand CAD | 19.25% |
| 2017 FY | -726.74 Thousand CAD | -0.8% |
| 2017 Q1 | -190.06 Thousand CAD | 21.91% |
| 2017 Q2 | -218.42 Thousand CAD | -14.92% |
| 2017 Q4 | -141.88 Thousand CAD | 19.56% |
| 2016 Q1 | -215.53 Thousand CAD | 69.43% |
| 2016 FY | -721 Thousand CAD | 48.78% |
| 2016 Q4 | -243.4 Thousand CAD | -117.8% |
| 2016 Q3 | -111.75 Thousand CAD | 25.65% |
| 2016 Q2 | -150.3 Thousand CAD | 30.26% |
| 2015 FY | -1.4 Million CAD | 51.2% |
| 2015 Q1 | -209.29 Thousand CAD | 70.74% |
| 2015 Q3 | -260.89 Thousand CAD | -12.36% |
| 2015 Q4 | -705.15 Thousand CAD | -170.29% |
| 2015 Q2 | -232.18 Thousand CAD | -10.94% |
| 2014 FY | -2.88 Million CAD | -1493.6% |
| 2014 Q3 | -2.05 Million CAD | -3889.1% |
| 2014 Q4 | -715.31 Thousand CAD | 65.12% |
| 2014 Q2 | -51.4 Thousand CAD | 22.11% |
| 2014 Q1 | -65.99 Thousand CAD | 0.0% |
| 2013 FY | -180.99 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Izotropic Corporation | -1.56 Million CAD | 16.002% |
| Sona Nanotech Inc. | -2.6 Million CAD | 49.532% |